- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03153774
Vurderinger av sarkopeni-prevalens hos pasienter med kronisk hjertesvikt og hos personer før TAVI (PRESAR-HF)
Vurderinger av sarkopeni-prevalens hos pasienter med kronisk hjertesvikt og hos personer før transkateter aortaklaffimplantasjon
The main objective was to assess the prevalence of sarcopenia in chronic heart failure patients and in patients before the trans aortic valvular implantation.
The loss of muscle mass in chronic heart failure patients is a prognostic factor for sarcopenia. The purpose was to identify in these patients signs of sarcopenia for a better management.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Age-related muscle loss, termed sarcopenia, affects 10% of elderly subjects aged 60-70 years and more than 30% above the age of 80. The concept of sarcopenia has been supported by the recent findings of muscular atrophy which was related to the decrease of protein synthesis because of the "anabolic resistance", affecting the muscular fibers type II. In fact, sarcopenia could be a consequence of chronic disease and not only an issue in the elderly people. The diagnosis is assessed by the weak muscle mass and the muscle strength and function. A description of these muscle parameters has been described in a study of 200 patients with NYHA class II-III and showed that 19,5 % have a decrease in muscle mass. They also showed that these patients have a lower functional ability. These findings prompted us to investigate the prevalence of sarcopenia in chronic heart failure subjects for a better management of these patients.
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
Auvergne
-
Clermont-Ferrand, Auvergne, Frankrike, 63003
- CHU Clermont-Ferrand
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Major patients (>18 years)
- Men or women
- Hospitalized in pre- trans aortic valvular implantation assessment in the cardiology department of the university hospital centre of Clermont-Ferrand or
- Patients with chronic heart failure in charge in the hospital of Clermont-Ferrand or convalescence in the pneumocardiological clinic of Durtol
Exclusion Criteria:
- Patient not affiliated to social security
- Inability to understand the information consent letter
- Not having signed informed consent
- Has a mental or legal incapacitation and is unable to provide informed consent.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Diagnostisk
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Heart failure patients
The main objective was to assess the prevalence of sarcopenia in chronic heart failure patients and in patients before the trans aortic valvular implantation. |
Handgrip test, Bioimpedance analysis (Bodystat), 6-min walking test, Short physical performance battery (balance test, 4-min walking test, 5 times getting-up test), Biological markers test, Trans-thoracic echography, Electrocardiogram 12 leads, Palm gripping test |
|
Eksperimentell: TAVI patients
The main objective was to assess the prevalence of sarcopenia in chronic heart failure patients and in patients before the trans aortic valvular implantation. |
Handgrip test, Bioimpedance analysis (Bodystat), 6-min walking test, Short physical performance battery (balance test, 4-min walking test, 5 times getting-up test), Biological markers test, Trans-thoracic echography, Electrocardiogram 12 leads, Palm gripping test |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Håndgrepstest
Tidsramme: på dag 1
|
på dag 1
|
|
|
Bioimpedance analysis data
Tidsramme: at day 1
|
Fat-free mass and body fat mass will be combined to report BMI in Kg/m2 |
at day 1
|
|
Short physical performance battery
Tidsramme: at day 1
|
Balance test, 4-min walking test, 5 times getting-up test |
at day 1
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Blood draw for serum creatinine in umol/L
Tidsramme: at day 1
|
Measure of inflammation |
at day 1
|
|
CRP in mg/L
Tidsramme: at day 1
|
Measure of inflammation |
at day 1
|
|
platelets in Giga/L
Tidsramme: at day 1
|
Measure of inflammation |
at day 1
|
|
complete blood count CBC (white blood cells in Giga/L and red blood cells in Tera/L)
Tidsramme: at day 1
|
Measure of inflammation |
at day 1
|
|
urea in mmol/L
Tidsramme: at day 1
|
Measure of inflammation |
at day 1
|
|
albumin in g/L
Tidsramme: at day 1
|
Measure of inflammation |
at day 1
|
|
NT-ProBNP in ng/L
Tidsramme: at day 1
|
Measure of inflammation |
at day 1
|
|
Electrocardiogram
Tidsramme: at day 1
|
Parameter which may interfere with sarcopenia |
at day 1
|
|
Trans-thoracic echography
Tidsramme: at day 1
|
Parameter which may interfere with sarcopenia |
at day 1
|
Samarbeidspartnere og etterforskere
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Blanquet M, Massoulie G, Boirie Y, Guiguet-Auclair C, Mulliez A, Anker S, Boiteux MD, Jean F, Combaret N, Souteyrand G, Riocreux C, Pereira B, Motreff P, Rossignol P, Clerfond G, Eschalier R. Handgrip strength to screen early-onset sarcopenia in heart failure. Clin Nutr ESPEN. 2022 Aug;50:183-190. doi: 10.1016/j.clnesp.2022.05.019. Epub 2022 Jun 6.
- Eschalier R, Massoullie G, Boirie Y, Blanquet M, Mulliez A, Tartiere PL, Anker S, D'Agrosa Boiteux MC, Richard R, Jean F, Combaret N, Souteyrand G, Riocreux C, Pereira B, Motreff P, Stolt P, Rossignol P, Clerfond G. Sarcopenia in patients after an episode of acute decompensated heart failure: An underdiagnosed problem with serious impact. Clin Nutr. 2021 Jun;40(6):4490-4499. doi: 10.1016/j.clnu.2020.12.033. Epub 2021 Jan 9.
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- CHU-324
- 2014-A00938-39 (Annen identifikator: 2014-A00938-39)
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .